The European Commission has given approval for a new Car-T therapy for adult patients with relapsed or refractory mantle cell lymphoma. Treatment options for people with this aggressive blood cancer are limited, and Anthony Nolan welcomes this development which will benefit patients.
Antonio Pagliuca, Chief Medical and Scientific Adviser at Anthony Nolan and Professor of Stem Cell Transplantation at King’s College Hospital NHS Foundation Trust, says:
“With mantle cell lymphoma, there is still a significant way to go to ensure patients have the best possible chance of survival.
“The conditional marketing authorisation is an important step towards delivering on that unmet need and offering patients an important new option in their fight against this cancer. It is good news that we will be able to offer this option to eligible patients as soon as possible.”